Business
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
BOSTON, April 02, 2026--PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/d21547322cd75c5f0f9801f61fd6eba1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VLmumtsaWczdu0gxwXF5tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwOA--/https://media.zenfs.com/en/business-wire.com/d21547322cd75c5f0f9801f61fd6eba1","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SehEdDKk5T42IltpW9ArQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA-/https://media.zenfs.com/en/business-wire.com/d21547322cd75c5f0f9801f61fd6eba1","width":1200,"height":385}},"lazy":false},{"type":"text","content":"BOSTON, April 02, 2026--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced positive topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgoTM (SPT-320TM or Glyph Agomelatine). GlyphAgo is a novel, Glyphed oral prodrug of agomelatine in development for generalized anxiety disorder (GAD) and the second clinical-stage candidate from Seaport’s pipeline.","length":645,"tagName":"p"},{"type":"text","content":"Based on the data shared today, Seaport announced plans to advance GlyphAgo into two parallel trials, a Phase 2a proof-of-pharmacology trial to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and a Phase 2b randomized placebo-controlled trial in GAD that is designed to be registration-enabling.","length":317,"tagName":"p"},{"type":"text","content":"The GlyphAgo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company’s strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech’s Founded Entity, Seaport Therapeutics.","length":347,"tagName":"p"},{"type":"text","content":"The full text of the announcement from Seaport is as follows:","length":61,"tagName":"p"},{"type":"text","content":"Seaport Therapeutics Announces Positive Proof of Con...